References
- Crabtree GW, Henderson JF. Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res 1971;31:985–91
- Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975;256:331–3
- Franchetti P, Grifantini M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem 1999;6:599–614
- Wu JC. Mycophenolate mofetil: molecular mechanism of action. Perspec Drug Discov Des 1994;2:185–204
- Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann NY Acad Sci 1993;696:88–93
- Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996;85:921–30
- Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients (US Renal Transplant Mycophenolate Mofetil Study Group). Transplantation 1995;60:225–32
- Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178–97
- Jain J, Almquist SJ, Shlyakhter D, Harding MW. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci 2000;90:625–37
- Jain J, Almquist SJ, Heiser AD, et al. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′-monophosphate dehydrogenase inhibitor. J Pharmcol Exper Ther 2002;302:1272–7
- Dhar TG, Shen Z, Guo J, et al. Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem 2002;45:2127–30
- Dhar TG, Shen Z, Gu HH, et al. 3-Cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2003;13:3557–60
- Stamos D, Trudeau M, Bethiel S. Inhibitors of IMPDH enzyme Patent WO0056331 (Vertex Pharma, USA)
- Yang N, Wang J, Li J, et al. A three-dimensional pharmacophore model for IMPDH inhibitors. Chem Biol Drug Des 2011;78:175–82
- Schrödinger Suite 2011 was available from Schrödinger, LLC, New York, NY, 2011
- Phase, version 3.3, Schrödinger, LLC, New York, NY, 2011
- Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening. 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647–71